ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

06 8 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

23 7 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 7 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

26 6 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

10 6 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 6 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

06 6 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

29 5 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

22 5 2025 14:12:58 提供 Nasdaq GlobeNewswire

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

15 5 2025 09:29:01 提供 Nasdaq GlobeNewswire

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

07 5 2025 11:18:26 提供 Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

06 5 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 5 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

17 4 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Announces Chief Financial Officer Transition

10 4 2025 16:30:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 4 2025 16:00:00 提供 Nasdaq GlobeNewswire

Arcutis and Padagis Agree to Stay Patent Lawsuit

02 4 2025 13:16:46 提供 Nasdaq GlobeNewswire

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

27 3 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

07 3 2025 08:00:00 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 3 2025 16:00:00 提供 Nasdaq GlobeNewswire